Showing results (61-70 of 79) with videos related to
Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2016
Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast CancerBarbara Ingold Heppner, Michael Untch, Carsten Denkert, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 23, 2017
Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 yearsBerit M Pfitzner, Bianca Lederer, Judith Lindner, et al.Breast Cancer Research : BCR|May 12, 2019
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixtoElena Laakmann, Isabell Witzel, Peter A Fasching, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2019
Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) TrialSherko Kuemmel, Johannes Holtschmidt, Bernd Gerber, et al.European Journal of Cancer (Oxford, England : 1990)|April 2, 2013
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44)Jens Huober, Peter A Fasching, Claus Hanusch, et al.Oncotarget|November 5, 2017
Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicityPeter A Fasching, Lothar Häberle, Brigitte Rack, et al.Cancers|April 12, 2022
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer PatientsHanna Huebner, Lothar Häberle, Volkmar Müller, et al.European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trialAndreas Schneeweiss, Volker Möbus, Hans Tesch, et al.Oncology Research and Treatment|March 1, 2018
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-StudyFabienne Schochter, Brigitte Rack, Marie Tzschaschel, et al.The New England Journal of Medicine|January 27, 2012
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancerGunter von Minckwitz, Holger Eidtmann, Mahdi Rezai, et al.Pageof 8